Analyst consensus rating
Tango Therapeutics Analyst Rating: none
TNGX is rated none by 12 analysts with a $44.75 target. As of 2026-09-02.
Direct answer
Tango Therapeutics's consensus rating is none.
12 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $44.75.
Forecast evidence checked September 2, 2026.
Get free Tango Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $22.35
- Average price target
- $44.75
- High price target
- $69.00
- Low price target
- $24.00
- Low target gap
- +7.4%
- Target upside
- +100.2%
- High target gap
- +208.7%
- Target range width
- 201.3%
- Consensus rating
- none
- Analysts
- 12
- Evidence date
- September 2, 2026
- Valid through
- September 9, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Tango Therapeutics?
Tango Therapeutics has a verified none consensus. The same dataset has an average price target of $44.75.
How far are Tango Therapeutics's low and high targets from the recorded price?
The low target implies +7.4%, while the high target implies +208.7%.
How many analysts are included in Tango Therapeutics's consensus?
The verified consensus includes 12 analysts.
How is Tango Therapeutics's target upside or downside calculated?
The average target of $44.75 is divided by the recorded price of $22.35, then one is subtracted to produce +100.2%. This does not guarantee a future return.
When was Tango Therapeutics's analyst forecast verified?
The data was verified on 2026-09-02. The dataset is valid through 2026-09-09.